Loading clinical trials...

Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C) | Clinical Trials | Clareo Health

Back to clinical trial search

Not Yet RecruitingPhase 3NCT05388500

Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)

RATIONALE: According to previous results from PHARE study, a subgroup of patients with low-risk cancer (\< 3 cm) without axillary lymph node involvement or small (\< 2 cm) with minimal lymph node invo...

Lead sponsor: Institut de cancérologie Strasbourg Europe•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Valérie SARTORI

CONTACT

368767223 v.sartori@icans.eu

Manon VOEGELIN, PhD

CONTACT

368767360 promotion-rc@icans.eu

Related studies

RECRUITINGPhase 1

HER2 Vaccine for Locally Advanced Breast Cancer

NCT06949410 · Breast Cancer, HER2-positive Breast Cancer

RECRUITINGPhase 1

A Phase 1/1b Study of IAM1363 in HER2 Cancers

NCT06253871 · HER2 Mutation-Related Tumors, HER2, and more

RECRUITINGNA

Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer

NCT04030507 · Breast Cancer, HER2-positive Breast Cancer, and more

RECRUITINGPhase 2

HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

NCT07459673 · Breast Cancer, HER2-positive Breast Cancer, and more

RECRUITINGPhase 2

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

NCT07102381 · HER2-positive Breast Cancer, Breast Cancer

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 27, 2022Terms

Trial snapshot

StatusNOT_YET_RECRUITING

PhasePHASE3

Enrollment800

Start dateDec 2022

Last updatedMay 27, 2022

Condition

HER2-positive Breast Cancer

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 27, 2022Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions